Contact Us | Log In
Search
Sensex: 35511.6 +251.30 Gold: Rs.29753.00
Nifty: 10894.7 +77.70 Silver: Rs.38989.00
You are here: IndiaNotes >> Companies
Sun Pharmaceutical Industries Ltd.
BSE : 524715 | NSE : SUNPHARMAEQ | ISIN : INE044A01028 | Sector : Pharmaceuticals and health care
BSE : 572.00 -4.25 (-0.74%)
NSE : 572.10 -4.60 (-0.80%)
Latest Quote
BSE: 19th Jan 2018
Open Price 577.10
High Price 579.95
Low Price 568.50
Prev. Close 576.25
Volume 3,800
52 Wk High 728.45
52 Wk Low 433.15
NSE: 19th Jan 2018
Open Price 580.00
High Price 580.65
Low Price 567.60
Prev. Close 576.70
Volume 183,701
52 Wk High 729.05
52 Wk Low 432.70
What Are Analysts Saying for Sun-Pharmaceutical-Industries-Ltd
Nifty outlook and recommendations for 18'Jan 18
Way2wealth | 18 Jan, 2018
Index penetrated the upper band of the channel formation and closed above 161.8% retracement of its previous swing move. Going forward, Nifty likely to rally towards 10860 above which the next probabl...
Nifty outlook and recommendations for 27'Dec 17
Way2wealth | 27 Dec, 2017
After a series of an attempt, the Nifty index successfully closed above the 10500 levels. Going forward, Nifty has an immediate resistance near 10565 above which we may see a further up move towards 1...
Sun Pharmaceuticals Q2FY18: Domestic business sees partial recovery; Reduce
Equirus Securities | 20 Nov, 2017
Sun Pharma’s (SUNP) 2QFY18 sales were in line with EE, while EBITDA and earnings came 10%/48% ahead of EE largely owing to lower R&D and other expenses. US sales declined ~US$ 40mn sequentially due to...
Sun Pharmaceutical Industries Q2FY18 in line; Recall of ANDAs could be precursor to resolution; Reduce
Prabhudas Lilladher | 16 Nov, 2017
Sun pharma retains its guidance of single-digit decline in sales with 20-22% EBITDA margin. While SUNP had 20% effective tax rate in Q1FY18 and guided for higher tax rate in FY18E, they expects there ...
Company update: Sun Pharmaceutical Industries
Prabhudas Lilladher | 09 Nov, 2017
Impact on Sun Pharma: With increase in R&D expenditure to 8-10% of sales from 6-8% earlier, Taro expects many derma products to be approved and launched from its 32 pending ANDAs in next 24 months. Th...
View all
Key Fundamentals
Market Cap (Rs. Cr.): ......................... 137,264.48
EPS - TTM (Rs.): ......................... 0.00
P/E Ratio (x): ......................... 0.00
Facevalue (Rs): ......................... 5.00
Latest Dividend (%): ......................... 10
Dividend Yield (%): ......................... 0.61
Book Value/Share (Rs.): ......................... 86.99
P/B Ratio (x): ......................... 6.58
Quick Links
* The links below will re-direct you to www.indianotes.com
  • Peer Comparison
  • Financials